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Abstract
The objective of this study was to evaluate Candida oral colonization in human immunodeﬁciency virus (HIV)-infected patients undergo-
ing long-term highly active antiretroviral therapy (ARV). The cross-sectional study included 331 HIV patients, diagnosed from 1983 to
2003. Oral swabs were performed, and Candida species were determined using ID 32C. Isolates were tested for antifungal susceptibility.
Clinical and laboratory data were collected to identify the association with Candida colonization. In total, 161 Candida isolates were
detected among 147 of the 331 patients (44%), independently of the time when HIV infection was diagnosed. Candida albicans strains
represented 137 (85%) of the isolates, and were susceptible to all of the tested antifungal drugs. Among the non-C. albicans strains, six
isolates were dose-dependently susceptible to ﬂuconazole, nine to itraconazole, and seven to ketoconazole. The isolation of Candida
was signiﬁcantly higher in patients with virological failure (83/147; p 0.0002) and CD4+ T-lymphocyte counts <200 cells/mm3 (30/83;
p 0.0003). Recovery of Candida in the oral cavity was independent of protease inhibitor (PI) usage (p 0.60). Colonized patients typically
underwent salvage therapy (p 0.003), and had more episodes of opportunistic fungal infections (p 0.046) and malignancies (p 0.004).
Oral Candida colonization in patients under ARV therapy was associated with the immunosupressed status of HIV-infected patients, i.e.
low number of CD4+ T-cells per cubic millimetre, failure of ARV therapy (salvage therapy), and higher number of opportunistic infec-
tions and malignancies. Despite the fact that PIs have in vitro antifungal activity, the use of this class of antiretroviral agent did not inﬂu-
ence the presence of Candida in the oral cavity of AIDS patients.
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Introduction
Oropharyngeal candidiasis (OPC) was a frequent disease in
human immunodeﬁciency virus (HIV)-infected patients before
the introduction of highly effective antiretroviral therapy
(ARV). HIV-infected patients were shown to harbour Candida
in the oral cavity more frequently than healthy subjects, the
proportion varying from 60% [1,2] to 88% when more than
one sample was collected [3]. In HIV patients, oral coloniza-
tion by Candida spp. has predicted the subsequent develop-
ment of OPC [3], and low plasma HIV RNA viral load has
been related to low oropharyngeal carriage of Candida spp.
and a reduced risk of developing symptomatic infections [4].
As compared to other at-risk groups [5], an increased inci-
dence of asymptomatic oral Candida albicans carriage has
been demonstrated in HIV-infected subjects.
Recent data [6] have shown that some antiretroviral pro-
tease inhibitors (PIs) act directly on the secretory aspartyl
protease, an important virulence factor of C. albicans, and
the use of this class of ARV might play a role in reducing
Candida carriage and recurrence of OPC in HIV patients [7].
Previous studies on this subject [7,8] produced contradic-
tory data regarding the association of the use of PIs, HIV
RNA viral count and CD4+ cell count with colonization and
the occurrence of OPC. However, as the survival rates of
HIV patients increased, some questions arose about the
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impact of long-term ARV therapy and Candida oral coloniza-
tion.
This study was conducted in an attempt to evaluate
patients undergoing long-term ARV therapy with respect to
Candida oral colonization, to determine the frequency of
HIV-infected patients harbouring Candida species in the oral
cavity, the susceptibility to antifungal drugs, the genomic
DNA of Candida species, and the conditions associated with
Candida oral colonization.
Materials and Methods
Settings
The hospital and clinics of the State University of Campinas
constitute a tertiary-care university hospital located in Camp-
inas, Sao Paulo, Brazil; this is the reference hospital for more
than 5 000 000 inhabitants, and is responsible for more than
65% of the HIV/AIDS patients in the reference area.
Data collection
A cross-sectional study was conducted at two outpatient
units from April 2003 to 2004. The patients were included
after they signed a consent form. Patients were eligible for
the study if they were HIV-positive, they had been under-
going treatment with three or more antiretroviral agents
for at least 1 year, without clinical and symptomatic evi-
dence of OPC, they were aged ‡18 years, and they had
not undergone antifungal therapy in the last 3 months.
Patient demographic data included: year of HIV diagnosis,
history of prior fungal infections, prior use of antifungal
therapy, last CD4+ cell count and HIV RNA viral load mea-
surements, detectable or undetectable HIV RNA viral load
(undetectable, <50 copies/mL), previous opportunistic infec-
tions, classes of ARV agents in use at the time of the study
(PIs—indinavir, and ritonavir-boosted PI; nucleoside reverse
transcriptase inhibitors (NRTIs)—zidovudine, stavudine, lam-
ivudine, didanosine, tenofovir, and abacavir; and non-nucleo-
side reverse transcriptase inhibitors—efavirenz and
nevirapine). The patients were classiﬁed, according to isola-
tion of Candida spp. from the oral cavity, as colonized or
non-colonized.
Mycological assessment and identiﬁcation of yeasts
Samples from the oral cavity were obtained by swabbing the
oral mucosa of the patients with a sterile cotton swab, pla-
ted onto Sabouraud dextrose agar plates supplemented with
chloramphenicol 0.5 g/L, and incubated for 48–72 h. Five to
ten colonies from the positive plates were then inoculated in
CHROMagar Candida plates (CHROMagar Microbiology,
Paris, France) and incubated at 30C for 48–72 h. Only one
sample was taken per patient.
Green colonies isolated in CHROMagar were presump-
tively identiﬁed as C. albicans, and they were cultured in
cornmeal–Tween-80 agar, at 25C for 7 days, for chlamydo-
spore formation. Additionally, the isolates were tested with
the ID 32C system for sugar assimilation (Biomerieux, Marcy
l’Etoile, France). Colonies presenting other colours were cul-
tured on new Sabouraud dextrose agar plates, and were
identiﬁed by standard methods and by ID 32C. All C. albicans
isolates were serotyped using a Candida Check Kit (Iatron
Laboratories Inc., Tokyo, Japan). C. albicans ATCC 28367,
serotype A, and C. albicans ATCC 44373, serotype B, were
tested as quality controls.
For presumptive identiﬁcation of Candida dubliniensis, all iso-
lates identiﬁed as green colonies in CHROMagar were cultured
at 42C, and growth was observed after 48 h [9]. If growth of
the colonies extended into the last three quadrants of the
plate, it was considered to be good growth, and if the growth
area was observed only in the ﬁrst quadrant, it was considered
to be poor growth. The xylose assimilation test was also per-
formed [10]. C. albicans ATCC 76615 and C. dubliniensis
CBS 7987 reference strains were tested as quality controls.
Candida isolates that did not grow at 45C and/or those
that did not assimilate xylose were submitted to genetic analy-
sis. D1/D2 regions of the large-subunit ribosomal DNA were
sequenced. Genomic DNA extraction from yeast was carried
out using the Instagene Matrix Kit (Bio Rad, Hercules, CA,
USA). D1/D2 regions were ampliﬁed according to the method
of Kurtzman and Robnett [11], using the following primer
set: NL-1, 5¢-GCATATCAATAAGCGGAAAAG; and NL-4,
5¢-GGTCCGTGTTTCAAGACGG. PCR ampliﬁcation was
performed for 30 cycles, with annealing at 52C, extension at
72C for 2 min, and denaturation at 94C for 1 min. The
ampliﬁed DNA was puriﬁed with SUPREC (Takara Bio Inc.,
Otsu, Shiga, Japan). The PCR products were directly
sequenced in both directions, using a Thermo Sequenase II
Dye Terminator Cycle Sequencing Kit (Amersham Pharmacia
Biotech Inc., NJ, USA) and the ABI 3100 PRIMS sequencer
(Applied Biosystems, Carlsbad, CA, USA). To determine
the sequences, the two following internal primers were
used, together with the above external primers: NL-2,
5¢-CTTGTTCGCTATCGGTCTC; and NL-3, 5¢-GAGA-
CCGATAGCGAACAAG. The nucleotide sequence data were
analysed using BLAST from the National Center for Biotech-
nology Information (http://www.ncbi.nlm.nih.gov).
Antifungal susceptibility testing
Antifungal susceptibility tests were performed using the
broth microdilution method, according to document M27-A2
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of the CLSI [12]. The antifungal drugs ﬂuconazole (Gerbras,
Sao Paulo, Brazil), itraconazole (Jansen Pharmaceutics, Titus-
ville, NJ, USA), 5-FC (A4888-1G; Sigma Chemical, St. Louis,
MO, USA), ketoconazole (Galera, Campinas, Sao Paulo,
Brazil), amphotericin B (Sigma Chemical) and nistatine
(141-05381; Wako Pure Chemical Industries, Ltd., Osaka,
Japan) were obtained as reagent-grade powders from their
respective manufacturers. Brieﬂy, broth microdilution testing
was performed in sterile, ﬂat-bottomed 96-well microplates
containing RPMI 1640 medium (L-glutamine without bicar-
bonate) buffered to pH 7.0 with MOPS.
A volume of 100 lL containing yeast cells was added to
each well to achieve a ﬁnal inoculum size of 0.5–
2.5 · 103 cells/mL. The plates were incubated at 35C for
48 h. Quality control strains (Candida parapsilosis ATCC
22019 and Candida krusei ATCC 6258) were included on
each day of the assay.
Electrophoretic karyotype (EK) determination
DNA preparation for EK determination was performed
according to Branchini et al. [13] EK determination was car-
ried out using the CHEF DRIII apparatus (Bio-Rad) under the
following electrophoretic conditions: 13C, 4.5 V, and
120C, and pulse intervals of 120 s for 18 h and 240 s for
22 h. Saccharomyces cerevisiae chromosome DNA size stan-
dards (Bio-Rad) were included in each gel as standards.
Analysis of the EK was performed by visual inspection of
photographs of ethidium bromide-stained gels. Each major
band and each minor band was identiﬁed, and the distance
from the origin of the gel, relative to those of the molecular
mass standards, was measured. Isolates were considered to
have different DNA subtypes if EK proﬁles differed by one
or more bands. The gels were also analysed by computer,
using the Bio-1D and BioGene V programs in a 95% CI (Vil-
ber Loumat, Marnes la Valle, France).
Statistical analysis
Continuous variables were assessed by means of two-tailed
Student’s t-test for differences in means. Categorical variables
in colonized and non-colonized patients were evaluated by chi-
square and Fisher tests, and a p-value of <0.05 was considered
to be statistically signiﬁcant. Continuous variables were analy-
sed using the non-parametric Mann–Whitney test (computa-
tional SAS system for Windows, version 8.02, Cary, NC, USA).
Results
Overall, 331 patients were enrolled in this study and, at the
time of the surveillance, 147 (44%) patients harboured Can-
dida spp. in the oral cavity. The patients were diagnosed for
HIV infection in different years, and the year of diagnosis of
HIV infection was compared with the onset of colonization.
Ninety patients were diagnosed as having HIV infection dur-
ing the period 1983–1995, and 43 (48%) were colonized; 241
patients participating in the study were diagnosed as having
HIV infection during the period 1996–2003, and 104 (43%)
were colonized (p 0.53) (Fig. 1).
Among the 331 patients, the mean age was 38.9 years
(colonized patients, 39.6 years; non-colonized patients,
38.3 years), 127 (38.4%) were women (colonized, 53; non-
colonized, 74), and the majority of patients were white (264/
331; colonized, 112; non-colonized, 152) (Table 1).
The number of colonized patients with detectable HIV
viral load was signiﬁcantly higher (83; 58.5%) than the num-
ber of non-colonized patients (68; 37%) (p 0.0002), and the
mean CD4 cell count in the colonized group was signiﬁcantly
lower (mean, 374.4; standard deviation, 243.5) than in the
non-colonized group (mean, 471.5; standard deviation, 306)
(p 0.0029). Table 2 shows the number of colonized and non-
colonized patients according to HIV RNA viral load and
intervals of CD4+ cell count. Patients with detectable HIV
viral load and CD4+ cell counts <200/mm3 were more likely
to be colonized (p 0.0003).
Most patients had at least one previous opportunistic infec-
tion, and they occurred at similar frequencies in colonized
(81%) and non-colonized patients (78%). When the number of
episodes of opportunistic infections were compared, fungal
infections, including superﬁcial and systemic infections, were
the most prevalent; 147 colonized patients and 184 non-colo-
nized patients had 105 and 150 episodes, respectively. How-
ever, when the fungal infections were categorized, colonized
patients had signiﬁcantly more previous episodes of oral can-
didiasis/OPC (55 episodes; p 0.046) and onychomycosis
(19 episodes; p 0.03) than non-colonized patients (OPC, 50
episodes; onychomycosis, 11 episodes) (Table 1).
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FIG. 1. Number of patients included in the study according to the
year of human immunodeﬁciency virus (HIV) diagnosis and oral cav-
ity Candida carriage status.
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It is of note that herpes zoster was the most frequent
viral opportunistic infection, and was signiﬁcantly more
frequent (33 episodes) in colonized than in non-colonized
patients (21 episodes) (p 0.007). Bacterial and protozoal
infections occurred to a similar extent in colonized and non-
colonized patients. Tuberculosis was distinctly prevalent in
the HIV population of the present study, i.e. 39 and 36 cases
in colonized and non-colonized patients, respectively (data
not shown).
ARV regimens containing two NRTIs + one non-nucleo-
side reverse transcriptase inhibitor and two NRTIs + one PI
or ritonavir-boosted PI were more commonly used in 85.6%
of the patients in the study (Table 3). At the time of this
research, two patients were receiving a fusion inhibitor. The
use of PI was not associated with colonization (p 0.44). Nev-
ertheless, patients who harboured Candida in the oral cavity
(30 patients) underwent salvage ARV therapy (which
included one or two PIs) signiﬁcantly more often than non-
colonized patients (p 0.003).
One hundred and sixty-one Candida strains were recov-
ered from the oral cavity of 147 colonized patients. C. albicans
represented 137 (85%) of the isolates; 117 were C. albicans
serotype A, and 20 strains were serotype B. In total, 24
(15%) non-C. albicans species were recovered, including: Can-
dida glabrata (seven), Candida tropicalis (four), Candida noverg-
ensis (three), C. krusei (two), C. dubliniensis (two),
C. parapsilosis (one), Candida kefyr (one), Candida lipolytica
(one), Candida guilhermondii (one), Candida sake (one), and
Candida calliculosa (one). Mixed colonization was detected in
12 patients. The years of diagnosis of HIV infection with ser-
otypes A and B were compared; among patients diagnosed
from 1983 to 1990, 83 and 14 were serotype A and sero-
type B, respectively, and among those diagnosed from 2000
to 2003, 31 and seven were serotype A and serotype B,
respectively (p 0.20).
Green colonies in CHROMagar were obtained with 139
Candida isolates. All were germ-tube-positive and were
tested for growth at 42C with assimilation of xylose. Ten
isolates were xylose assimilation-negative and seven failed to
grow, and three isolates grew poorly at 42C. These ten
TABLE 2. Human immunodeﬁciency virus (HIV) RNA viral
load and intervals of CD4+ cell counts in HIV-infected
patients as correlated with oral Candida colonization
Viral load
Colonized
(n = 142)
Non
colonized
(n = 182)
Total
(n = 324)
p-Valuen % n % n
‡50 copies/mL CD4+ cells/mm3
>350 35 25 71 39 106 –
200–350 21 15 31 17 52 –
<200 3 2 12 7 15 –
Total 59 42 114 63 173 –
<50 copies/mL CD4+ cells/mm3
>350 26 18 34 19 60 –
200–350 27 19 21 11 48 –
<200 30 21 13 7 43 0.0003
Total 83 58 68 37 151 –
TABLE 1. Characteristics of 331 human immunodeﬁciency
virus (HIV)-1-infected patients participating in this study as
correlated with oral Candida colonization
Parameter
Colonized
n = 147 (%)
Non-colonized
n = 184 (%) p-Value
Age: mean (years) 39.6 38.3 –
Gender: female 53 (36) 74 (40) –
Exposure to HIV
Sexual 118 (80.3) 148 (80.5) –
Sexual + IDU 29 (19.7) 35 (19) –
Vertical – 1 (0.5) –
HVI RNA viral load
Detectable
83 (58.5) 68 (37) 0.0002a
CD4+ cells/mm3
Median
326.5 410.5 0.0029b
Opportunistic infections
Presence of at least one episode
117 (80) 156 (85) –
Fungal infections
Pneomocistisjiroveci 25 (17) 29 (15.7) –
Oral candidiasis 55 (37.4 50 (27.1) 0.046
Cryptococosis 5 (3.4) 11 (5.9) –
Onychomycosis 19 (13) 11 (5.9) 0.028
Other systemic mycosis 5 (3.4) 5 (2.7) –
Viral infections
Herpes zoster 33 (22.4) 21 (11.4) 0.007
Malignancies
Non-Hodgkin lymphoma 4 (2.7) 0 0.038c
Use of protease inhibitor 83 (56.4%) 95 (51.6%) –
Previous use of antifungal 74 (50.3) 79 (42.9) –
Fluconazole 32 33 –
Ketoconazole 38 33 –
Itraconazole 1 6 –
Nistatine 48 37 0.009
Amphotericin B 3 10 –
IDU, intravenous drug use.
aChi-square test.
bMann–Whithney test.
cFisher exact test.
TABLE 3. Antiretroviral regimen for the 331 human
immunodeﬁciency virus-infected patients participating in
this study and Candida oral colonization
Antiretroviral
regimen
Colonized
(n = 147)
Non-
colonized
(n = 184)
Total
(n = 331)
p-Valuen % n % n %
Two NRTI + PI 53 36 71 38.5 124 37.4 –
Two NRTI +
NNRTI
64 43.5 89 48.3 153 46.2 –
Salvage therapya 30 20.4 24 13 54 16.3 0.003
Salvage therapy: Two NRTIs + NNRTI + PI; two NRTIs + NNRTI + two PIs;
two NRTIs + two/three PIs; NRTI + NNRTI + PI/NRTI + two PIs; NRTI +
PI + FI.
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor; FI, fusion inhibitor.
aColonized patients underwent salvage therapy more often than non-colonized
patients (p 0.003).
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strains were then sequenced, and two of them were 99%
compatible with C. dubliniensis.
EK determination identiﬁed 15 DNA proﬁles among 117
C. albicans serotype A, and proﬁles A1 and A3 were the
most predominant, representing 55.6% and 18%, respectively.
C. albicans serotype B had only three different EK proﬁles. It
is of note that one of the EK proﬁles of C. albicans serotype B
was identical to the A1 proﬁle (Fig. 2). The two C. dubliniensis
strains had two different proﬁles, which were also different
from all C. albicans proﬁles and from that of the reference
strain, C. dubliniensis CBS 7987.
Candida isolates mainly exhibited good susceptibility to the
tested antifungal drugs (Table 4). C. albicans serotypes A and
B were susceptible to all tested antifungal drugs. No resis-
tance to azoles was detected among the 159 isolates, includ-
ing C. albicans and non-C. albicans. However, isolates of
C. glabrata were found that were dose-dependently suscepti-
ble to ﬂuconazole (three isolates), to ketoconazole (six iso-
lates), and to itraconazole (seven isolates); one isolate of
C. tropicalis was dose-dependently susceptible to itraconazole,
and one isolate of C. novergensis was dose-dependently sus-
ceptible to ﬂuconazole.
C. krusei isolates were dose-dependently susceptible to all
azoles, as this species is intrinsically resistant to this antifun-
gal class. The data for the nine patients with non-C. albicans
isolates that were dose-dependently susceptible to at least
one antifungal drug were analysed, and antifungal agents had
previously been used in seven patients (C. glabrata, four of
seven patients; C. tropicalis, one patient; C. novergensis, one
patient). The previous exposure to antifungal agents did not
correlate with higher MIC levels; 74 patients had previously
used antifungal agents in the colonized group, and higher
MIC levels were detected only for non-C. albicans isolates,
independently of the use of antifungal agents.
Discussion
The prevalence of HIV patients harbouring Candida yeasts in
the oral cavity was similar to that found in previous studies
[1,14,15]. In the present study, 45% of HIV-infected patients
harboured Candida in the oral cavity, and 72% of the total iso-
lates were C. albicans serotype A. Serotype A represented
85% of all C. albicans isolates, which is in contrast to the ﬁnd-
ings of some studies that found a higher percentage of sero-
type B isolates [16,17] in AIDS patients and in patients with
different degrees of immunosuppression [16]. Whether the
serotype was A or B had no relationship with the duration of
HIV infection. Other studies, such as the present one,
reported serotyping of C. albicans and a higher relative fre-
quency of serotype A in clinical samples [18,19]. It is of note
that the present EK ﬁndings showed surprising genotype
diversity in serotype A strains (15 DNA proﬁles), as compared
to serotype B strains (three DNA proﬁles). Previous studies
[20,21] did not correlate serotypes and EK proﬁles in C. albi-
cans isolates from the oral cavity of HIV-infected patients, and
the low diversity previously reported might be related to a
particular serotype or to geographical distributions.
In the present study population, non-C. albicans accounted
for 15% of the isolates, suggesting an increasing number of
these species in Candida oral colonization [15,22]. The identi-
ﬁcation of C. dublinensis in the oral cavity of HIV patients in
Brazil has been repeatedly low [23,24] as compared with
other studies [25]. C. dubliniensis has been cited as having
replaced C. albicans in patients undergoing ﬂuconazole treat-
ment [26].
All C. albicans strains in the present study were susceptible
to all tested antifungal agents (Table 4), independently of the
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FIG. 2. Electrophoretic karyotypes of Candida albicans isolates from
the oral cavity of HIV-infected patients. (a) Lanes 2 to 14: C. albicans
serotype A. Lane 2: C. albicans serotype A, genotype A1. Lane 15:
C. albicans serotype B, genotype B1 identical to proﬁle A1. (b) C. albi-
cans serotype B. Lane 1 of each gel: Saccharomyces cerevisiae chromo-
some DNA size standards (kb).
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use of PIs and previous antifungal agents. Migliorati et al. [6]
reported in vitro results obtained using Candida yeast
pre-exposed to ritonavir before susceptibility testing, show-
ing that the percentage of resistant isolates decreased con-
siderably. The susceptibility proﬁles of the C. albicans isolates
in the present study, indicating susceptibility to the tested
antifungal drugs, could not be explained by the use of PIs. It
is of note that the number of patients who previously
received antifungal treatment was similar in both groups, i.e.
colonized (50.3%) and non-colonized (43%) patients, suggest-
ing that previous exposure to antifungal agents did not inter-
fere with antifungal susceptibility. As expected, non-
C. albicans isolates, i.e. C. glabrata and C. krusei, were dose-
dependently susceptible to azoles, independently of previous
use of antifungal drugs.
The present results show that detectable HIV RNA viral
load and CD4+ cell counts <200 cells/mm3 were signiﬁcantly
more frequent in patients harbouring Candida in the oral cav-
ity (p 0.003). Other authors have reported similar results
[27–29]. A national study conducted by Costa et al. [1]
showed no relationship between CD4+ cell count, HIV RNA
viral load, and oral Candida colonization; however, among
the patients included in their study, only nine patients had a
CD4 cell count <200 cells/mm3. Gottfredsson et al. [4]
reported an association between oral colonization and
plasma levels of HIV RNA, but they also did not ﬁnd a cor-
relation between CD4+ cells and oral Candida colonization;
unlike the present data, the median CD4+ cell counts of the
patients were basically identical in both groups, i.e. colonized
(382 cells/mL) and non-colonized (381 cells/mL). Considered
together, these ﬁndings suggest that the different results
obtained in the studies might correlate with the patient char-
acteristics in each study population.
The use of PIs in the ARV regimen did not inﬂuence the
carriage of Candida in the oral cavity in the present study.
Considering the previous studies on the effect of PIs in
reducing the recurrence of oral candidiasis [30,31], it was
expected that the use of PIs could decrease Candida oral car-
riage. The present results strongly suggested that the
immune status of the patients determined the higher preva-
lence of yeast carriage, and not the usage of PIs. It is of par-
ticular interest that the HIV-infected patients who harboured
Candida in the oral cavity typically underwent salvage ARV,
unlike those who were non-carriers, corroborating the
hypothesis that Candida colonization was mainly determined
by the immune status of the patients.
The study population involved a substantial number of
patients as compared with previous studies, and included
patients undergoing long-term ARV therapy. When the per-
centage of oral carriage of Candida according to the year of
HIV diagnosis was analysed, signiﬁcant differences were not
found between patients diagnosed during the period 1983–
1995 and those diagnosed in recent years, independently of
the ARV regimen. For instance, ﬁve patients were diagnosed
as having HIV/AIDS during the period 1983–1988, and only
11 patients started ARV therapy in 2003. Interestingly,
the duration of ARV therapy was not correlated with the
carriage status. It was expected that patients undergoing
prolonged ARV therapy and receiving PIs might harbour
Candida less frequently, on the basis of the potential
antifungal activity of these drugs according to in vitro studies
[17,32] and clinical data [33].
TABLE 4. Susceptibility to antifungal agents of 161 isolates of Candida spp. from the oral cavity of human immunodeﬁciency
virus-infected patients
Candida spp. (161)
Range of MIC (mg/L)
Fluconazole Ketoconazole Itraconazole Flucytosine Amphoteri-
cin B
Nistatine
Candida albicans (137)
Serotype A (117) 0.125–2 0.03–0.06 0.01–0.125 <0.125–2 0.125–1 0.50–2
MIC50 0.5 MIC50 0.03 MIC50 0.03 MIC50 <0.125 MIC50 0.5 MIC50 1
MIC90 1 MIC90 0.03 MIC90 0.06 MIC90 0.125 MIC90 1 MIC90 2
Serotype B (20) 0.125–2 0.03–0.50 0.03–0.125 <0.125–1 0.25–1 1–2
MIC50 0.5 MIC50 0.03 MIC50 0.06 MIC50 0.5 MIC50 0.5 MIC50 1
MIC90 1 MIC90 0.06 MIC90 0.125 MIC90 0.5 MIC90 0.5 MIC90 2
Non-C. albicans (24)
Candida glabrata (7) 8–16 0.125–0.50 0.25–0.50 <0.125–0.25 0.25–1 0.50–2
Candida tropicalis (4) 0.25–2 0.03–0.125 0.03–0.50 <0.125–0.125 0.25–1 2
Candida norvegensis (3) 4–16 003–0.125 0.06–0.125 0.25–2 0.50–1 1–2
Candida krusei (2) 16 0.125–0.25 0.125–0.25 1–2 0.50–1 2
Candida dubliniensis (2) 0.25 0.03 0.06 <0.125 0.125–0.25 1
Candida parapsilosis (1) 1 0.03 0.06 <0.125 0.50 2
Candida guilhermondi (1) 4 0.03 0.03 <0.125 0.125 1
Candida keﬁr (1) 0.50 0.03 0.03 0.125 0.50 0.50
Candida sake (1) 1 0.06 0.06 <0.125 0.06 0.50
Candida calliculosa (1) – – – – – –
Candida lipolytica (1) – – – – – –
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It is of note that the HIV patients carrying Candida in the
oral cavity had signiﬁcantly more opportunistic infections,
e.g. previous oral candidiasis, onychomycosis, and herpes
zoster, and four patients had non-Hodgkin lymphoma. As
compared to the non-colonized patients, these ﬁndings were
substantially consistent with laboratory data that showed a
signiﬁcantly lower mean number of of CD4+ cells per cubic
millimetre and a detectable HIV RNA viral load. Other
authors have also described the correlation between low
CD4+ count and occurrence of herpses zoster [34]. Glesby
et al. [35] found that HIV-infected women with CD4+ counts
<200 cells/mm3 were substantially more likely to develop
shingles.
In conclusion, the present data suggest that the immune
status of the HIV-infected patients was probably the most
important factor for harbouring of Candida spp. in the oral
cavity. Colonized patients were signiﬁcantly more immunosu-
pressed than non-colonized patients. Effective ARV therapy
appeared to be fundamental in determining an undetectable
viral load and a higher CD4+ cell count in HIV-infected
patients, rather than the use of PIs. These ﬁndings underscore
the complexity of Candida oral colonization in HIV-infected
patients undergoing ARV therapy. As new classes of antiret-
roviral agents are being released, additional studies involving
longitudinal follow-up will be required.
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